Effective November 30, 2016, the Ontario Public Drug Programs will begin funding INFLECTRA™ (infliximab) as a limited use benefit for the following new indications:
LU Code 477 - For the treatment of ulcerative colitis in patients who meet clinical criteria.
LU Code 478 - For the treatment of moderate to severe Crohn’s ... Read More
28
Nov2016
13
Oct2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2016:
37 negotiations are currently underway with no new files added since the last update of August 31, 2016.
118 joint negotiations have been completed with 4 files successfully negotiated ... Read More
08
Sep2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2016:
40 negotiations are currently underway with 10 files added since the last update of July 31, 2016:
Cotellic (cobimetinib): used to treat metastatic melanoma
Fabrazyme (agalsidase beta): used to treat ... Read More
17
Aug2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2016:
32 negotiations are currently underway with 2 files added since the last update of June 30, 2016:
Avastin (bevacizumab): used to treat genitourinary platinum-resistant ovarian cancer
Opdivo (nivolumab): used to ... Read More
12
Jul2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2016:
33 negotiations are currently underway with 8 files (including 2 biosimilars) added since the last update of May 31, 2016:
Abilify (aripiprazole): used for the treatment of schizophrenia and related ... Read More
20
Jun2016
In February 2015, PDCI Market Access (PDCI) released a report entitled pCPA Negotiation Guidelines. That report, which was a collaboration between the pan-Canadian Pharmaceutical Alliance (pCPA) and PDCI, was meant to provide guidance to manufacturers on pCPA’s expectations surrounding negotiations.
Although the pCPA Negotiation Guidelines report outlined how manufacturers should ... Read More
18
May2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2016:
23 negotiations are currently underway with 5 files added since the last update on March 31, 2016:
Arnuity Ellipta (fluticasone furoate): used for the treatment of asthma;
Breo Ellipta (fluticasone furoate/vilanterol): used for ... Read More
19
Apr2016
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued the First Principles for Subsequent Entry Biologics (SEBs) to guide negotiations and inform expectations. These principles are now available on the pCPA website, found here.
The pCPA has also updated the status of negotiations on brand name drugs, included in ... Read More
11
Apr2016
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued manufacturers a notification of first principles for subsequent entry biologics (SEBs) to guide negotiations and inform expectations. This information has not yet been posted on the pCPA website but is being shared with their permission.
Please see below for a copy ... Read More
23
Feb2016
In a recent update released to their website, the pan-Canadian Pharmaceutical Alliance (pCPA) announced 2 significant developments:
The Federal Drug Plans are now participating in the pCPA; and
The Office of the pCPA (the Office) is now fully staffed.
On January 19, 2016 the Government of Canada issued a News Release ... Read More